scholarly journals Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa

2020 ◽  
Vol Volume 12 ◽  
pp. 527-534
Author(s):  
Ammar Almaaytah
Keyword(s):  
Middle East ◽  
North Africa ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
P Budget

scholarly journals Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements

2020 ◽  
Vol Volume 12 ◽  
pp. 233-240 ◽  
Author(s):  
Helen Phillips-Jackson ◽  
Clive Hallam ◽  
Niamh Cullen ◽  
Terry Pearson ◽  
Mark Gilman ◽  
...  
Keyword(s):  
Impact Analysis ◽  
Budget Impact ◽  
Opioid Use Disorder ◽  
Budget Impact Analysis ◽  
Prolonged Release ◽  
Opioid Use ◽  
Resource Requirements ◽  
P Budget

scholarly journals Budget impact analysis of the new reimbursement policy for day surgery in Thailand

2019 ◽  
Vol Volume 12 ◽  
pp. 41-55
Author(s):  
Rapeepong Suphanchaimat ◽  
Jutatip Thungthong ◽  
Kriddhiya Sriprasert ◽  
Kanjana Tisayaticom ◽  
Chulaporn Limwattananon ◽  
...  
Keyword(s):  
Impact Analysis ◽  
Budget Impact ◽  
Day Surgery ◽  
Budget Impact Analysis ◽  
Reimbursement Policy ◽  
P Budget

scholarly journals Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain

2019 ◽  
Vol Volume 11 ◽  
pp. 757-765
Author(s):  
Maria Cevey ◽  
Jaime Calvo-Alén ◽  
Carlos Crespo ◽  
Angel Robles-Marhuenda ◽  
Lee Smolen ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Systemic Lupus ◽  
P Budget

scholarly journals PIN150 Economic VALUE of Treatment and Vaccine Technologies to Address the COVID-19 Pandemic: A Cost-Effectiveness and Budget IMPACT Analysis

2020 ◽  
Vol 23 ◽  
pp. S568
Author(s):  
W. Padula ◽  
S. Malaviya ◽  
N. Reid ◽  
F. Chingcuanco ◽  
J. Ballreich ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Impact Analysis ◽  
Budget Impact ◽  
Economic Value ◽  
Budget Impact Analysis

scholarly journals AB0634 BUDGET IMPACT ANALYSIS OF BIOLOGICAL THERAPY COMPARED TO CONVENTIONAL SPONDYLOARTHRITIS TREATMENT, IN A FOURTH LEVEL HOSPITAL IN BOGOTA COLOMBIA

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1612.2-1613
Author(s):  
J. M. Bello-Gualtero ◽  
O. J. Calixto ◽  
G. Salguedo ◽  
Y. M. Chamorro-Melo ◽  
C. A. Camargo Rodríguez ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Annual Cost ◽  
Impact Analysis ◽  
Budget Impact ◽  
Biological Therapy ◽  
Biologic Therapy ◽  
Disease Diagnosis ◽  
Budget Impact Analysis ◽  
Military Hospital ◽  
Number Of Patients

Background:Spondyloarthritis refers to a family of diseases, of which ankylosing spondylitis and non-radiographic axial spondyloarthritis are responsible for axial impairment. Previously, the only treatment available were NSAIDs, which control activity and stop radiological progression, but at the expense of increased adverse effects, such as cardiovascular risk, dyspepsia and chronic renal failure. For the past 2 decades, biological therapy has been available, which means an increase in care costs.Objectives:The objective of this study is to perform a budget impact analysis of biologic therapy.Methods:To do a budget impact analysis from the perspective of the payer, comparing biological therapy with coventional therapy for the treatment of spondyloarthritis. Demographic characterization of the population attended at the Central Military Hospital. Time horizon from 2012 to 2018, taking the activity count according to the hospital’s billing and the prices of the activities of the state body SISMED. Exchange rates at the end of 2018.Results:The patients attended were 117, mostly men (63, 25%), average age 46, 4 years (SD 13), with disease diagnosis time of 9, 8 years (SD 9, 6). In the budget impact analysis, it is observed that 25% of patients were on DMARDs therapy, 22% with NSAIDs and 96% with biologic therapy. The average year/patient cost with NSAIDs alone would be EUR 381, with DMARDs only EUR 9,318 and, if only biological therapy was used, EUR 423. Within the total number of patients, the average annual cost, including the possibility of combining these drugs, amounted to EUR 5,403Conclusion:Including biological therapy in the care of patients with spondyloarthritis can increase up to 24 times the annual cost per patient. This increase is not only due to higher market value, it also relates to the need for more medical procedures and diagnostic follow-up tests.References:[1]Strömbeck, et al. Cost of Illness from the Public Payers’ Perspective in Patients with Ankylosing Spondylitis in Rheumatological Care. J Rheumatol 2010;37;2348-2355.Disclosure of Interests:None declared

Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer

2012 ◽  
Vol 16 (1) ◽  
pp. 96-107 ◽  
Author(s):  
Laure Benjamin ◽  
Valérie Buthion ◽  
Michaël Iskedjian ◽  
Bechara Farah ◽  
Catherine Rioufol ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Impact Analysis ◽  
Budget Impact ◽  
Metastatic Breast ◽  
Budget Impact Analysis ◽  
Cancer Drugs ◽  
Her2 Positive ◽  
Anti Cancer

PDB21 Budget IMPACT Analysis of a Flash Glycose Monitoring Technology in Greece

2021 ◽  
Vol 24 ◽  
pp. S81
Author(s):  
O. Siskou ◽  
A. Koutsovasilis ◽  
J. Doupis ◽  
I. Karagkouni ◽  
O. Konstantakopoulou ◽  
...  
Keyword(s):  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Monitoring Technology
Sign in / Sign up

Export Citation Format

Share Document